Encouraging results from the open label trial of Ambroxol
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
A pre-clinical study has shown that low dose insulin administered through the nose can improve movement and help protect dopaminergic neurons from damage.
A phase II open label trial of a novel drug targeting
A prostrate drug (Terazosin) has been shown to exert neuroprotective effects in animal models.
AUDIO VERSION AVAILABLE.
Regular home-based aerobic exercise appears to reduce the progression of Parkinson’s.
AUDIO VERSION AVAILABLE.